TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Hai-Dong Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.